Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Melanoma (US)

Product Code:
Publication Date:
February 2016

Compare 7 leading melanoma drugs. Find out how lower-ranked rivals are threatening top brands

When oncologists can’t prescribe the drugs they want, brands lose market share—share that goes to the competition.

That’s a big concern for the leading brand in the US melanoma treatment market. Prescription limitations are helping the 2nd, and even 4th place brands gain ground.

The report compares 7 leading melanoma treatments—Keytruda, Mekinist, Opdivo, Proleukin, Tafinlar, Yervoy, and Zelboraf. You’ll get a detailed picture of what prevents doctors from prescribing your brand, who you’re losing market share to, and who you’re taking it from.

That’s information you can use to win back lost share and compete more effectively.

Not your market? Click here to see the EU5 report


Request Sample Pages

Get Answers to Key Questions about Melanoma Drug Brands

  • Keytruda (pembrolizumab; Merck & Co.): Which top-3 brand does Keytruda lose the most share to?
  • Mekinist (trametinib; Novartis): Is cost or availability costing Mekinist more market share?
  • Opdivo(nivolumab; Bristol-Myers Squibb): Could eliminating barriers help other top-3 brands beat Opdivo?
  • Proleukin (aldesleukin; Prometheus): Few oncologists surveyed use Proleukin now, but how many would consider prescribing it?
  • Tafinlar (dabrafenib; GlaxoSmithKline): Do more US oncologists prescribe Tafinlar or Mekinist?
  • Yervoy (ipilimumab; Bristol-Myers Squibb): Are the barriers driving Yervoy’s share gains related more to cost or labelling?
  • Zelboraf (vemurafenib; Genentech): Eliminating barriers would put Zelboraf ahead of two other brands. Which two?

Top Takeaways

  • Only three brands benefit from barriers: These brands all saw a net gain in market share, while the other four saw net losses.
  • Barriers have a limited overall effect: In the US, few oncologists experience more than one barrier with any given brand.
  • Market share impact small but significant: While few brands gain or lose more than 1%, that’s enough to change the rankings at the top and middle of the market.
  • “Market-access” barriers have the greatest effect: barriers related to cost and reimbursement affect more prescriptions that any other barrier.
  • Competition is fierce at the top of the market: The two leading brands are neck and neck, while the third place brand straddles the top and middle of the market.
  • Bottom of the market shows a clear loser: The bottom-ranking brand is prescribed by 42% fewer physicians than the next brand up.
  • Barrier effect significant for “other” brands: In aggregate, “other” brands not surveyed gain more market share than 5 of the surveyed brands.
  • Important differences between US and Europe: In terms of both the brands most prescribed and the effect barriers have on prescribing. See the EU5 report for details. 

Exploring Market Access Issues

Market Access Impact: Melanoma explores key issues affecting melanoma drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest effect?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 Medical Oncologists in the US, chosen from the largest community of validated physicians in the world

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between January 4th and 19th, 2016.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved